William Blair downgraded FibroGen to Market Perform from Outperform without a price target after the company’s Phase 3 ZEPHYRUS-1 study did not meet the primary endpoint. The stock in premarket trading is down 79% to $3.40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FGEN:
- FibroGen Tanks after Phase 3 Data in Pulmonary Fibrosis Disappoints
- FibroGen to implement cost reduction effort to extend runway into 2026
- FibroGen announces upcoming milestones
- FibroGen says Phase 3 ZEPHYRUS-1 study did not meet primary endpoint
- FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis